Non-animal Alternative Testing Market - By Product (Organs-on-chip, Tissue Line), Method (Ex vivo, Computer Modelling), Technology (Cell Culture, High Throughput), Application (Infectious, Immunological), End-use (Biotech Companies, CRO)- Global Forecast to 2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationNon-animal Alternative Testing Market - By Product (Organs-on-chip, Tissue Line), Method (Ex vivo, Computer Modelling), Technology (Cell Culture, High Throughput), Application (Infectious, Immunological), End-use (Biotech Companies, CRO)- Global Forecast to 2032
Non-animal Alternative Testing Market Size
Non-Animal Alternative Testing Market size was valued at USD 1.7 billion in 2022 and will progress tremendously to reach over USD 4.5 billion by 2032 at 10.3% CAGR. The high market growth is owing to the rising emphasis on animal welfare as part of global sustainable development goals.
While animal models are critical to biomedical research for drug and treatment developments, research agencies are encouraging the adoption of complementary approaches or alternatives to animal testing. Additionally, adoption of the 3R principles (replacement, reduction, and refinement) by both regulatory bodies and end-use industries, specifically in the field of pharmaceuticals is expected to drive the market for non-animal alternative testing during projection period.
Non-animal alternative testing are methods for replacing animals used in experiments such as clinical studies for drug development with algorithms and computational programs in order to avoid animal cruelty and maintain ethical practices while achieving maximum accuracy in experiments such as finding potential drug molecules.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Non-animal Alternative Testing Market Size in 2022 | USD 1.7 Billion |
| Forecast Period | 2023 to 20232 |
| Forecast Period 2023 to 20232 CAGR | 10.3% |
| 20232 Value Projection | USD 4.5 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 180 |
| Tables, Charts & Figures | 342 |
| Segments covered | Product type, Method, Technology, Application, End-use and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
The COVID-19 pandemic had a minimal impact on the growth of the global non-animal alternative testing market in 2020. During the pandemic period, the pharmaceutical industry experienced a significant increase in the demand for medicines as people became more concerned about their health and well-being. Additionally, a number of drug developers resisted working in wet laboratories or coming in direct contact with animals and humans during pre-clinical drug testing. As a result, demand for non-animal alternative testing has increased significantly, promoting the rise of the market during the pandemic period.
Non-animal Alternative Testing market Trends
Pre-clinical studies give information on the safety and efficacy of a potential drug prior to testing it on humans. Such research involves proper preclinical models to compare it to the real-world population in order to obtain accurate results. Studies on animals are helping researchers discover regarding potential drug toxicity and dosing. As a result, the demand for drug research and development grows as well as the demand for animal models also increases, thereby fostering the market trends.
Further, PETA and Cruelty-Free International agencies are pressurising on the end-user industry to switch animal models to the alternate methods that ensure no animals are harmed, abused, or used in any way that affects the animal as well as people's sentiments. Hence, the awareness pertaining to non-animal alternative testing will propel the market outlook.
Non-animal Alternative Testing Market Analysis
Based on product type, the non-animal alternative testing market is segmented into organs-on-chips, cell lines, and tissue lines. The organ-on-chips segment dominated in 2022 with a market size of USD 872.9 million. The advantages of organ-on-chips (OOCs) over cell culture, animal models, and human clinical trials have attracted the interest of both the medical and pharmaceutical communities, that are working on producing personalised medicines.
For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) established a novel concept for Organs-on-a-Chip to investigate treatments for inflammatory diseases and ailments. Organs-on-a-chip are made up of millions of cells arranged on a platform to mimic the functioning of various organs and can be used as a tool for assessing and developing new treatments for complicated diseases without the usage of animals. Such benefits offered by OOCs is expected to propel the segmental growth.
Based on technology, the non-animal alternative testing market is segmented into cell culture technology, high throughput technology, molecular imaging, and omics technology. The cell culture technology segment accounted for USD 746.9 million in 2022. The increase is due to the fact that researchers frequently utilise cell culture technologies for analysing a large number of test results at once. Also, numerous pharmacological experiments are performed on eukaryotic cells, preferably human cells, that have been cultured under strictly monitored in vitro conditions to mimic the external environment of the human body.
Imagine you're about to test a new medicine for a nasty infection. You've got two choicestry it on animals or find an alternative way to test it without harming any furry friends. The choice is clear, right? Well, that's exactly what's happening in the world of scientific testing. There's a growing demand for ways to test drugs and other products without using animals. And one of the biggest areas where this is happening is in the fight against infectious diseases. Why? Because guess what? A lot of those nasty infections we humans get can actually come from animals. In fact, experts think it's true for more than 6 out of 10 of the ones we know about. Plus, most of the new or scary infectious diseases that pop up come from animals too. So, it makes sense that we're looking for ways to test treatments for those diseases without putting animals at risk. And that's where non-animal alternative testing comes in. This means using things like cells, tissues, or computer models to test drugs and treatments, instead of animals. And guess what? It's working! In 2022, the non-animal alternative testing market was growing by about 7.8% each year, and it's expected to keep growing. That means we're getting closer and closer to a future where we can test new medicines and treatments without harming any animals.
Who's using the non-animal testing market? Well, it's like this symphony orchestrayou've got the pharmaceutical companies with their drug-making violins, the biotech companies with their genetic harps, and the cosmetics industry painting beautiful tunes on noses and lips. Research institutes and academics are the conductors, guiding the music, while contract research organizations (CROs) are the nimble assistants. And don't forget the other players, like universities and scientists who love this kind of research. The pharmaceutical industry is like the star soloist, projected to grow a whopping 11% every year. Why? Because they're racing to find new cures for all sorts of ailments. Plus, people are increasingly saying "no" to using animals for testing, so these companies are switching to computer-based methods to stay on everyone's good side. So, the non-animal testing market is set to explode like fireworks in the night sky during the next few years.
North America non-animal alternative testing market surpassed USD 653.8 million in 2022 with a growth rate of 8.2%. The region is dominating due to the presence of key players in these regions along with rising government support for non-animal alternative testing. Also, increasing prevalence of chronic diseases along with investment by key players in R&D activities to develop novel product is expected to supplement the market landscape.
Non-animal Alternative Testing Market Share
The global non-animal alternative testing industry comprises several players including
- AlveoliX AG,
- MIMETAS
- MatTek Corporatio
- Emulate, Inc
- VITROCELL Systems GmbH
- Bio-Rad Laboratories, Inc.
- Hurel Corporation
- Evotec SE
- MB Research Laboratories
- TissUse GmbH.
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.
Some of the recent industry developments
- In September 2022, the National Medical Commission issued guidelines for pharmacology students in India, intended to promote the study of drug effects using simulation or computational models and replace the use of rats, rabbits, and guinea pigs. Such initiatives, alongside rapid technological innovation, will boost the usage of non-animal alternative testing in medical research.
The non-animal alternative testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Product Type
- Organ-on-chips
- Cell lines
- Tissue lines
By Method
- Ex vivo testing
- Computer modelling
- Cellular assay
- Biochemical assay
By Technology
- Cell culture technology
- High throughput technology
- Molecular imaging
- Omics technology
By Application
- Infectious diseases
- Immunological diseases
- Oncology
- Cardiovascular diseases
- Diabetes
- Genetic diseases
- Neurological diseases
By End-use
- Pharmaceutical companies
- Biotechnological companies
- Research institutes and academics
- Contract research organization
- Other end-user
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy